SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-281152
Filing Date
2020-10-29
Accepted
2020-10-29 17:00:29
Documents
3
Group Members
FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II GENERAL PARTNER LLCFLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II, L.P.FLAGSHIP PIONEERING, INC.FLAGSHIP VENTURES FUND V GENERAL PARTNER LLCFLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLCFLAG

Document Format Files

Seq Description Document Type Size
1 SC 13D d36897dsc13d.htm SC 13D 157214
2 EX-99.1 d36897dex991.htm EX-99.1 11118
3 EX-99.4 d36897dex994.htm EX-99.4 49409
  Complete submission text file 0001193125-20-281152.txt   219672
Mailing Address ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Ventures Fund V, L.P. (Filed by) CIK: 0001627639 (see all company filings)

IRS No.: 611749444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Subject) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91795 | Film No.: 201273441
SIC: 2834 Pharmaceutical Preparations